TQFL13
TQFL13 is derivative of Thymoquinone (TQ) (HY-D0803) with potent anti-breast cancer activity. TQFL13 exhibits higher cytotoxicity against breast cancer cells (BT549, MDA-MB-231, 4T1). TQFL13 increases apoptosis and blocks the cell cycle at S and G2/G1 phases in breast cancer cells. TQFL13 shows dose-dependent anti-tumor efficacy in mouse breast cancer allograft model. TQFL13 can be used for the study of breast cancer.
For research use only. We do not sell to patients.
- CAS No.: 2822560-46-1
- Formula: C20H23NO5
- Molecular Weight:357.40
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
TQFL13 (0-160 μM, 24 h) exerts cytotoxic activity against BT549, MDA-MB-231, 4T1 breast cancer cells and normal MCF-10A cells, with IC50 values of 23.80 μM, 37.55 μM, 17.59 μM, and > 100 μM, respectively[1].
TQFL13 (48 h) displays anti-viability activity against BT549, MDA-MB-231, 4T1 breast cancer cells and normal MCF-10A cells, with IC50 values of 12.35 μM, 12.14 μM, 12.21 μM, and >100 μM, respectively[1].
TQFL13 (0-20 μM, 24 h) increases apoptosis in 4 T1 cells and blocks the cell cycle at S and G2/G1 phases in BT549 and MDA-MB-231 breast cancer cells[1].
TQFL13 (2.5-5 μM, 0-54 h) inhibits 4 T1 cell growth, migration, and invasion[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:4 T1 and MDA-MB-231 breast cancer cells
-
Concentration:0, 5, 10, 20 μM
-
Incubation Time:24 h
-
Result:Induced the apoptosis.
Reduced the full-length PARP and BCL-2.
Increased the level of BAX.
-
Cell Line:BT549 and MDA-MB-231 breast cancer cells
-
Concentration:0, 5, 10, 20 μM
-
Incubation Time:24 h
-
Result:Blocked the cell cycle at S and G2/G1 phases.
Downregulated the level of CyclinB1, CyclinD1and p53.
Upregulated the level of phosphorylated p53 (ser15).
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:4T1 mouse breast cancer cells were injected into the fourth mammary fat pads of female BALB/c mice to construct a breast cancer lung metastasis model [1]
-
Dosage:3.75, 7.5, 15 mg/kg
-
Administration:i.p., starts 4 days after 4T1 cell inoculation into mammary fat pads, continues until day 30
-
Result:Showed dose-dependent anti-tumor efficacy.
Showed no significant changes in body weight.
Altered the morphology of breast tumor cells.
Exerted anti-tumor activity by regulating cell apoptosis and cell cycle signaling pathways.
Chemical Information
-
CAS No. 2822560-46-1
-
Molecular Weight 357.40
-
Formula C20H23NO5
-
SMILES
COC1=CC=C(C(OC)=C1OC)/C=N/C2=C(C(C=C(C2=O)C(C)C)=O)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
TQFL13 Related Classifications
HY-175846 Related Classifications
Powered by Bioz